inSoma Bio, Inc.
inSoma Bio develops bio-inspired solutions for reconstructive plastic surgery, utilizing nature’s own designs to create unique products that enable surgeons to use a person’s own tissue instead of synthetic implants and fillers. Their mission is to improve patient outcomes by developing injectable materials that mimic human tissue for safer and more accurate tissue rebuilding.
Industries
Nr. of Employees
small (1-50)
Products
Injectable recombinant protein-based scaffold for soft-tissue reconstruction
An injectable, genetically engineered protein matrix that is liquid at room temperature and self-assembles at body temperature into a porous scaffold to support and stabilize co-injected autologous tissue (e.g., fat) for reconstructive procedures.
Injectable recombinant protein-based scaffold for soft-tissue reconstruction
An injectable, genetically engineered protein matrix that is liquid at room temperature and self-assembles at body temperature into a porous scaffold to support and stabilize co-injected autologous tissue (e.g., fat) for reconstructive procedures.
Services
In-house preclinical study execution (including animal models), preparation for GMP scale-up, and development of regulatory and reimbursement strategies to support clinical evaluation of reconstructive biomaterials.
In-house preclinical study execution (including animal models), preparation for GMP scale-up, and development of regulatory and reimbursement strategies to support clinical evaluation of reconstructive biomaterials.
Expertise Areas
- Biomaterials engineering
- Thermoresponsive material design
- Recombinant protein engineering
- Soft-tissue reconstructive applications (fat grafting, breast and facial reconstruction)
Key Technologies
- Recombinant protein engineering
- Thermoresponsive biomaterials
- Injectable porous scaffold formation
- Autologous fat grafting co-injection
News & Updates
inSoma received support from NIH for developing a 3D cell culture platform for organoids and stem cells, validated by the University of Chapel Hill.
inSoma received a grant from NSF to further develop the Fractomer product for soft tissue reconstruction.
inSoma announced the close of its seed round, building on previous funding and grants.
NIH awarded inSoma a grant to explore Fractomer as a support matrix for skin grafting in burn wounds.
NCBiotech awarded inSoma funding to advance Fractomer through commercialization.
inSoma received a grant to develop a scaffold as a natural alternative to silicone implants for breast reconstruction.
inSoma received support from NIH for developing a 3D cell culture platform for organoids and stem cells, validated by the University of Chapel Hill.
inSoma received a grant from NSF to further develop the Fractomer product for soft tissue reconstruction.
inSoma announced the close of its seed round, building on previous funding and grants.
NIH awarded inSoma a grant to explore Fractomer as a support matrix for skin grafting in burn wounds.
NCBiotech awarded inSoma funding to advance Fractomer through commercialization.
inSoma received a grant to develop a scaffold as a natural alternative to silicone implants for breast reconstruction.